Eric R. A. Vos, Cheyenne C. E. van Hagen, Denise Wong, Gaby Smits, Marjan Kuijer, Alienke J. Wijmenga-Monsuur, Joanna Kaczorowska, Robert S. van Binnendijk, Fiona R. M. van der Klis, Gerco den Hartog, Hester E. de Melker
{"title":"荷兰在关注变异体时代的 SARS-CoV-2 血清流行趋势：为未来应对措施提供参考","authors":"Eric R. A. Vos, Cheyenne C. E. van Hagen, Denise Wong, Gaby Smits, Marjan Kuijer, Alienke J. Wijmenga-Monsuur, Joanna Kaczorowska, Robert S. van Binnendijk, Fiona R. M. van der Klis, Gerco den Hartog, Hester E. de Melker","doi":"10.1111/irv.13312","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>To inform future response planning we aimed to assess SARS-CoV-2 trends in infection- and/or vaccine-induced immunity, including breakthrough infections, among (sub)groups, professions and regions in the Dutch population during the Variant of Concern (VOC)-era.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this prospective population-based cohort, randomly selected participants (<i>n</i> = 9985) aged 1–92 years (recruited early-2020) donated home-collected fingerstick-blood samples at six timepoints in 2021/2022, covering waves dominated by Alpha, Delta, and multiple Omicron (sub-)variants. IgG antibody assessment against Spike-S1 and Nucleoprotein was combined with vaccination- and testing data to estimate infection-induced (inf) and total (infection- and vaccination-induced) seroprevalence.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Nationwide inf-seroprevalence rose modestly from 12% (95% CI 11–13) since Alpha to 26% (95% CI 24–28) amidst Delta, while total seroprevalence increased rapidly to 87% (95% CI 85–88), particularly in elderly and those with comorbidities (i.e., vulnerable groups). Interestingly, highest infection rates were noticeable among low/middle educated elderly, non-Western, those in contact professions, adolescents and young adults, and in low-vaccination coverage regions. Following Omicron emergence, inf-seroprevalence elevated sharply to 62% (95% CI 59–65) and further to 86% (95% CI 83–90) in late-2022, with frequent breakthrough infections and decreasing seroprevalence dissimilarities between most groups. Whereas > 90% of < 60-year-olds had been infected at least once, 30% of vaccinated vulnerable individuals had still not acquired hybrid immunity.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Groups identified to have been infected disproportionally during the acute phase of the pandemic require specific attention in evaluation of control measures and future response planning worldwide. Furthermore, ongoing tailored vaccination efforts and (sero-)monitoring of vulnerable groups may remain important.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13312","citationCount":"0","resultStr":"{\"title\":\"SARS-CoV-2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response\",\"authors\":\"Eric R. A. Vos, Cheyenne C. E. van Hagen, Denise Wong, Gaby Smits, Marjan Kuijer, Alienke J. Wijmenga-Monsuur, Joanna Kaczorowska, Robert S. van Binnendijk, Fiona R. M. van der Klis, Gerco den Hartog, Hester E. de Melker\",\"doi\":\"10.1111/irv.13312\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>To inform future response planning we aimed to assess SARS-CoV-2 trends in infection- and/or vaccine-induced immunity, including breakthrough infections, among (sub)groups, professions and regions in the Dutch population during the Variant of Concern (VOC)-era.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>In this prospective population-based cohort, randomly selected participants (<i>n</i> = 9985) aged 1–92 years (recruited early-2020) donated home-collected fingerstick-blood samples at six timepoints in 2021/2022, covering waves dominated by Alpha, Delta, and multiple Omicron (sub-)variants. IgG antibody assessment against Spike-S1 and Nucleoprotein was combined with vaccination- and testing data to estimate infection-induced (inf) and total (infection- and vaccination-induced) seroprevalence.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Nationwide inf-seroprevalence rose modestly from 12% (95% CI 11–13) since Alpha to 26% (95% CI 24–28) amidst Delta, while total seroprevalence increased rapidly to 87% (95% CI 85–88), particularly in elderly and those with comorbidities (i.e., vulnerable groups). Interestingly, highest infection rates were noticeable among low/middle educated elderly, non-Western, those in contact professions, adolescents and young adults, and in low-vaccination coverage regions. Following Omicron emergence, inf-seroprevalence elevated sharply to 62% (95% CI 59–65) and further to 86% (95% CI 83–90) in late-2022, with frequent breakthrough infections and decreasing seroprevalence dissimilarities between most groups. Whereas > 90% of < 60-year-olds had been infected at least once, 30% of vaccinated vulnerable individuals had still not acquired hybrid immunity.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Groups identified to have been infected disproportionally during the acute phase of the pandemic require specific attention in evaluation of control measures and future response planning worldwide. Furthermore, ongoing tailored vaccination efforts and (sero-)monitoring of vulnerable groups may remain important.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13544,\"journal\":{\"name\":\"Influenza and Other Respiratory Viruses\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13312\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Influenza and Other Respiratory Viruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/irv.13312\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13312","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
背景 为了给未来的应对计划提供信息，我们旨在评估荷兰人口中（亚）群体、职业和地区在关注变异体（VOC）时代的 SARS-CoV-2 感染和/或疫苗诱导免疫（包括突破性感染）趋势。 方法 在这个基于人群的前瞻性队列中，随机抽取了 1-92 岁的参与者（n = 9985）（2020 年初招募），他们在 2021/2022 年的六个时间点捐献了家庭采集的指血样本，涵盖了以 Alpha、Delta 和多个 Omicron（亚）变异为主的波段。针对 Spike-S1 和 Nucleoprotein 的 IgG 抗体评估与疫苗接种和检测数据相结合，以估算感染诱发的血清流行率（inf）和总血清流行率（感染和疫苗接种诱发）。 结果 全国inf血清流行率从阿尔法以来的12%（95% CI 11-13）小幅上升至德尔塔期间的26%（95% CI 24-28），而总血清流行率迅速上升至87%（95% CI 85-88），尤其是在老年人和有合并症的人（即弱势群体）中。有趣的是，中低学历老年人、非西方人、从事接触性职业的人、青少年和年轻人以及疫苗接种覆盖率低的地区的感染率最高。奥米克龙出现后，婴儿血清流行率急剧上升至 62%（95% CI 59-65），到 2022 年底进一步上升至 86%（95% CI 83-90），突破性感染频繁发生，大多数群体之间的血清流行率差异不断缩小。90%的 60 岁老人至少感染过一次，而 30% 接种过疫苗的易感人群仍未获得混合免疫力。 结论 在大流行的急性期，被发现感染比例过高的群体需要在评估控制措施和未来全球应对计划时予以特别关注。此外，对易感人群进行有针对性的疫苗接种和（血清）监测可能仍然很重要。
SARS-CoV-2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response
Background
To inform future response planning we aimed to assess SARS-CoV-2 trends in infection- and/or vaccine-induced immunity, including breakthrough infections, among (sub)groups, professions and regions in the Dutch population during the Variant of Concern (VOC)-era.
Methods
In this prospective population-based cohort, randomly selected participants (n = 9985) aged 1–92 years (recruited early-2020) donated home-collected fingerstick-blood samples at six timepoints in 2021/2022, covering waves dominated by Alpha, Delta, and multiple Omicron (sub-)variants. IgG antibody assessment against Spike-S1 and Nucleoprotein was combined with vaccination- and testing data to estimate infection-induced (inf) and total (infection- and vaccination-induced) seroprevalence.
Results
Nationwide inf-seroprevalence rose modestly from 12% (95% CI 11–13) since Alpha to 26% (95% CI 24–28) amidst Delta, while total seroprevalence increased rapidly to 87% (95% CI 85–88), particularly in elderly and those with comorbidities (i.e., vulnerable groups). Interestingly, highest infection rates were noticeable among low/middle educated elderly, non-Western, those in contact professions, adolescents and young adults, and in low-vaccination coverage regions. Following Omicron emergence, inf-seroprevalence elevated sharply to 62% (95% CI 59–65) and further to 86% (95% CI 83–90) in late-2022, with frequent breakthrough infections and decreasing seroprevalence dissimilarities between most groups. Whereas > 90% of < 60-year-olds had been infected at least once, 30% of vaccinated vulnerable individuals had still not acquired hybrid immunity.
Conclusions
Groups identified to have been infected disproportionally during the acute phase of the pandemic require specific attention in evaluation of control measures and future response planning worldwide. Furthermore, ongoing tailored vaccination efforts and (sero-)monitoring of vulnerable groups may remain important.
期刊介绍：
Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases.
Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
